Chiyanika Chileka, Shumbayawonda Elizabeth, Pansini Michele, Liu Kin Hung, Yip Terry Cheuk-Fung, Wong Vincent Wai-Sun, Chu Winnie Chiu Wing
Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China.
Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Clin Obes. 2025 Feb;15(1):e12712. doi: 10.1111/cob.12712. Epub 2024 Oct 22.
To evaluate the relationship between serum gamma-glutamyl transferase (GGT) levels and fatty pancreas in subjects with concurrent obesity, insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD) without a history of pancreatitis. From March 2019 to September 2021, 31 adult subjects with concurrent obesity and MASLD were recruited as part of the study investigating the biological impact of bariatric surgery and lifestyle modification on obesity. Chemical shift encoded MRI of the abdomen, LiverMultiScan, anthropometric, clinical and blood biochemistry analyses were performed prior to any intervention at baseline. GGT (p <.001) was significantly different between those 'with fatty pancreas' and 'without fatty pancreas' groups. GGT (p <.001) was significantly different between those 'with both metabolic syndrome and fatty pancreas' and those 'with metabolic syndrome but without fatty pancreas.' GGT (p <.001) was also significantly different between those 'with both diabetes and fatty pancreas' and those 'with diabetes but without fatty pancreas'. Logistic regression analysis showed that abnormal GGT levels (p = .010) and Hypertension (p = .045) were significant independent predictors of fatty pancreas. GGT was associated with fatty pancreas by an odds ratio 7.333 (95% [CI]: 1.467-36.664), while the AUROC of GGT in determining fatty pancreas was 0.849. Elevation in serum GGT might be a potential marker to identify fatty pancreas.
为评估在无胰腺炎病史、合并肥胖、胰岛素抵抗及代谢功能障碍相关脂肪性肝病（MASLD）的受试者中，血清γ-谷氨酰转移酶（GGT）水平与胰腺脂肪变性之间的关系。2019年3月至2021年9月，招募了31名合并肥胖和MASLD的成年受试者，作为研究减肥手术和生活方式改变对肥胖的生物学影响的一部分。在基线进行任何干预之前，对腹部进行化学位移编码磁共振成像（LiverMultiScan）、人体测量、临床和血液生化分析。“有胰腺脂肪变性”组和“无胰腺脂肪变性”组之间的GGT（p＜0.001）有显著差异。“合并代谢综合征和胰腺脂肪变性”者与“合并代谢综合征但无胰腺脂肪变性”者之间的GGT（p＜0.001）有显著差异。“合并糖尿病和胰腺脂肪变性”者与“合并糖尿病但无胰腺脂肪变性”者之间的GGT（p＜0.001）也有显著差异。逻辑回归分析显示，GGT水平异常（p = 0.010）和高血压（p = 0.045）是胰腺脂肪变性的显著独立预测因素。GGT与胰腺脂肪变性的比值比为7.333（95%[CI]：1.467 - 36.664），而GGT在确定胰腺脂肪变性方面的曲线下面积（AUROC）为0.849。血清GGT升高可能是识别胰腺脂肪变性的潜在标志物。
